Skip to main content
. 2022 Jan 20;12:1068. doi: 10.1038/s41598-022-05209-8

Table 3.

Outcomes of the entire study population and subgroups of patients who received adjuvant trastuzumab and those who did not receive adjuvant trastuzumab.

Variables All patients
N = 91 (%)
Treatment group
N = 39 (%)
Control
N = 52 (%)
p value
Recurrence 12 (13) 3 (10) 9 (17) 0.22
Biopsy proven 12 3 9
Type of recurrence
Local 6 (7) 1 (3) 5 (10) 0.23
Distant 1 (2) 0 1 (2) 1.0
New primary cancer 5 (6) 2 (6) 3 (6) 1.0
Breast cancer recurrence 7 (8) 1 (3) 6 (12) 0.23